| Michael A Morone, MD | |
|
2825 8th Ave N, Billings, MT 59101-0909 | |
| (406) 238-2500 | |
| Not Available |
| Full Name | Michael A Morone |
|---|---|
| Gender | Male |
| Speciality | Neurosurgery |
| Experience | 34 Years |
| Location | 2825 8th Ave N, Billings, Montana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1407954456 | NPI | - | NPPES |
| 117480100 | Other | WY | MDCD PIN |
| 0048416 | Other | MT | MDCD PIN |
| 312453 | Other | WY | BCBS PIN |
| 000091445 | Other | MT | BCBS PIN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207T00000X | Neurological Surgery | 10138 (Montana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Billings Clinic | Billings, MT | Hospital |
| Livingston Healthcare | Livingston, MT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Billings Clinic | 6002993516 | 659 |
| Billings Clinic | 6002993516 | 659 |
News Archive
Orbis Education, a developer of nursing education solutions, has announced the completion of its $8 million Series B financing, led by Lightspeed Venture Partners of Menlo Park, California.
Researchers have identified additional resistance mechanisms that could be targeted to improve the efficacy of irreversible epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small-cell lung cancer harbouring both EGFR and T790M mutations.
Many patients with melanoma need a sentinel-lymph-node biopsy to determine if cancer cells have spread there, but a positive finding doesn't mean all the lymph nodes in the area must be removed, according to new international study.
Thyroid cancer is a disease with good cure rates in most cases. In 5% of patients, however, the tumor becomes refractory to the available therapies and may spread all over the body, causing death.
› Verified 7 days ago
| Entity Name | Billings Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346288347 PECOS PAC ID: 6002993516 Enrollment ID: O20080527000137 |
News Archive
Orbis Education, a developer of nursing education solutions, has announced the completion of its $8 million Series B financing, led by Lightspeed Venture Partners of Menlo Park, California.
Researchers have identified additional resistance mechanisms that could be targeted to improve the efficacy of irreversible epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small-cell lung cancer harbouring both EGFR and T790M mutations.
Many patients with melanoma need a sentinel-lymph-node biopsy to determine if cancer cells have spread there, but a positive finding doesn't mean all the lymph nodes in the area must be removed, according to new international study.
Thyroid cancer is a disease with good cure rates in most cases. In 5% of patients, however, the tumor becomes refractory to the available therapies and may spread all over the body, causing death.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael A Morone, MD Po Box 35100, Billings, MT 59107-5100 Ph: (406) 238-2500 | Michael A Morone, MD 2825 8th Ave N, Billings, MT 59101-0909 Ph: (406) 238-2500 |
News Archive
Orbis Education, a developer of nursing education solutions, has announced the completion of its $8 million Series B financing, led by Lightspeed Venture Partners of Menlo Park, California.
Researchers have identified additional resistance mechanisms that could be targeted to improve the efficacy of irreversible epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small-cell lung cancer harbouring both EGFR and T790M mutations.
Many patients with melanoma need a sentinel-lymph-node biopsy to determine if cancer cells have spread there, but a positive finding doesn't mean all the lymph nodes in the area must be removed, according to new international study.
Thyroid cancer is a disease with good cure rates in most cases. In 5% of patients, however, the tumor becomes refractory to the available therapies and may spread all over the body, causing death.
› Verified 7 days ago
Vance L. Fredrickson, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 801 N 29th St, Billings, MT 59101 Phone: 406-238-2500 | |
Stuart G. Goodman, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 1041 N 29th St, Billings, MT 59101 Phone: 406-237-5577 Fax: 406-237-5575 | |
Mr. Michael L Copeland, MD PHD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 1041 N 29th St, Billings, MT 59101 Phone: 406-237-5577 Fax: 406-237-5575 | |
Dr. Marlin Dustin Richardson, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 801 N 29th St, Billings, MT 59101 Phone: 406-238-2500 | |
Eugen Dolan, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 801 N 29th St, Billings, MT 59101 Phone: 406-238-2500 | |
Dr. Lashman W Soriya, MD Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 2900 12th Ave N, Suite 340 W, Billings, MT 59101 Phone: 406-237-5760 Fax: 406-237-5799 |